– GUD to Great –
MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) ("Knight") is pleased to announce that Samira Sakhia will assume the role of President and Chief Executive Officer, Knight Therapeutics Inc., effective September 1, 2021. Ms. Sakhia currently serves as Knight's President and Chief Operating Officer.
Jonathan Ross Goodman will assume the role of Executive Chairman and will help direct Knight's strategy through his role as Executive Chairman of the Board and by providing the full benefit of his 27 years of experience, leadership and guidance. At 17.2% ownership, Jonathan remains Knight's largest shareholder.
Also effective September 1, 2021, James Gale will transition to the role of lead director. Jim has been Chair of Knight's Board since founding on February 28th, 2014.
“I have worked side by side with Samira for 18 years where I have had the privilege of watching her develop into a seasoned, top brass executive. Knight is my baby, and as such, I would only entrust its stewardship to the best and brightest. As Executive Chairman and Knight's largest shareholder, I will remain engaged and focused on non-operational areas where I can add the most value,” said Jonathan Ross Goodman
“It has been a privilege to have worked hand-in-hand with and learned from Jonathan for the last twenty years,” said Samira Sakhia. “I am …
Full story available on Benzinga.com